nodes	percent_of_prediction	percent_of_DWPC	metapath
Prazosin—MT3—urinary bladder cancer	0.623	1	CbGaD
Prazosin—ABCB1—Mitomycin—urinary bladder cancer	0.0364	0.166	CbGbCtD
Prazosin—SLC22A2—Cisplatin—urinary bladder cancer	0.0286	0.13	CbGbCtD
Prazosin—ABCG2—Fluorouracil—urinary bladder cancer	0.0248	0.113	CbGbCtD
Prazosin—ABCG2—Carboplatin—urinary bladder cancer	0.0247	0.112	CbGbCtD
Prazosin—ABCG2—Cisplatin—urinary bladder cancer	0.0211	0.096	CbGbCtD
Prazosin—ABCG2—Etoposide—urinary bladder cancer	0.0207	0.0943	CbGbCtD
Prazosin—ADRA1B—vas deferens—urinary bladder cancer	0.0147	0.283	CbGeAlD
Prazosin—ABCG2—Doxorubicin—urinary bladder cancer	0.0141	0.0643	CbGbCtD
Prazosin—ABCG2—Methotrexate—urinary bladder cancer	0.0137	0.0623	CbGbCtD
Prazosin—ABCB1—Gemcitabine—urinary bladder cancer	0.0105	0.0476	CbGbCtD
Prazosin—ABCB1—Cisplatin—urinary bladder cancer	0.0076	0.0346	CbGbCtD
Prazosin—ABCB1—Etoposide—urinary bladder cancer	0.00747	0.034	CbGbCtD
Prazosin—ABCB1—Doxorubicin—urinary bladder cancer	0.0051	0.0232	CbGbCtD
Prazosin—ABCB1—Methotrexate—urinary bladder cancer	0.00494	0.0225	CbGbCtD
Prazosin—MT3—prostate gland—urinary bladder cancer	0.00326	0.0627	CbGeAlD
Prazosin—KCNH6—prostate gland—urinary bladder cancer	0.00232	0.0447	CbGeAlD
Prazosin—KCNH6—renal system—urinary bladder cancer	0.00158	0.0305	CbGeAlD
Prazosin—ADRA1D—prostate gland—urinary bladder cancer	0.00129	0.0248	CbGeAlD
Prazosin—KCNH6—female reproductive system—urinary bladder cancer	0.00127	0.0244	CbGeAlD
Prazosin—ORM1—prostate gland—urinary bladder cancer	0.00106	0.0204	CbGeAlD
Prazosin—MT3—lymph node—urinary bladder cancer	0.00104	0.02	CbGeAlD
Prazosin—ADRA1D—epithelium—urinary bladder cancer	0.000945	0.0182	CbGeAlD
Prazosin—SLC22A2—renal system—urinary bladder cancer	0.000936	0.018	CbGeAlD
Prazosin—SLC22A3—prostate gland—urinary bladder cancer	0.000927	0.0179	CbGeAlD
Prazosin—ADRA1B—renal system—urinary bladder cancer	0.000896	0.0173	CbGeAlD
Prazosin—ADRA1D—urethra—urinary bladder cancer	0.000861	0.0166	CbGeAlD
Prazosin—SLC22A3—seminal vesicle—urinary bladder cancer	0.000784	0.0151	CbGeAlD
Prazosin—ADRA1A—prostate gland—urinary bladder cancer	0.000738	0.0142	CbGeAlD
Prazosin—KCNH2—prostate gland—urinary bladder cancer	0.000713	0.0137	CbGeAlD
Prazosin—ADRA1D—female reproductive system—urinary bladder cancer	0.000702	0.0135	CbGeAlD
Prazosin—SLC22A1—renal system—urinary bladder cancer	0.000661	0.0127	CbGeAlD
Prazosin—SLC22A3—smooth muscle tissue—urinary bladder cancer	0.000656	0.0126	CbGeAlD
Prazosin—ABCG2—prostate gland—urinary bladder cancer	0.000634	0.0122	CbGeAlD
Prazosin—SLC22A3—renal system—urinary bladder cancer	0.000632	0.0122	CbGeAlD
Prazosin—SLC22A3—urethra—urinary bladder cancer	0.000621	0.012	CbGeAlD
Prazosin—KCNH2—seminal vesicle—urinary bladder cancer	0.000603	0.0116	CbGeAlD
Prazosin—ORM1—female reproductive system—urinary bladder cancer	0.000578	0.0111	CbGeAlD
Prazosin—ADRA2A—prostate gland—urinary bladder cancer	0.000561	0.0108	CbGeAlD
Prazosin—HTR1A—renal system—urinary bladder cancer	0.000546	0.0105	CbGeAlD
Prazosin—ADRA1A—epithelium—urinary bladder cancer	0.000543	0.0105	CbGeAlD
Prazosin—ABCG2—seminal vesicle—urinary bladder cancer	0.000537	0.0103	CbGeAlD
Prazosin—HTR1D—female reproductive system—urinary bladder cancer	0.000525	0.0101	CbGeAlD
Prazosin—SLC22A3—female reproductive system—urinary bladder cancer	0.000506	0.00974	CbGeAlD
Prazosin—ADRA1A—renal system—urinary bladder cancer	0.000503	0.00969	CbGeAlD
Prazosin—KCNH2—renal system—urinary bladder cancer	0.000486	0.00936	CbGeAlD
Prazosin—SLC22A1—vagina—urinary bladder cancer	0.000479	0.00922	CbGeAlD
Prazosin—KCNH2—urethra—urinary bladder cancer	0.000477	0.0092	CbGeAlD
Prazosin—ADRA2A—seminal vesicle—urinary bladder cancer	0.000475	0.00915	CbGeAlD
Prazosin—SLC22A3—vagina—urinary bladder cancer	0.000458	0.00881	CbGeAlD
Prazosin—CYP1A1—epithelium—urinary bladder cancer	0.000443	0.00852	CbGeAlD
Prazosin—ABCG2—urethra—urinary bladder cancer	0.000425	0.00818	CbGeAlD
Prazosin—CYP1A1—renal system—urinary bladder cancer	0.000411	0.00791	CbGeAlD
Prazosin—CYP1A1—urethra—urinary bladder cancer	0.000403	0.00777	CbGeAlD
Prazosin—KCNH2—female reproductive system—urinary bladder cancer	0.000389	0.0075	CbGeAlD
Prazosin—ADRA2A—urethra—urinary bladder cancer	0.000376	0.00724	CbGeAlD
Prazosin—KCNH2—vagina—urinary bladder cancer	0.000352	0.00678	CbGeAlD
Prazosin—ORM1—lymph node—urinary bladder cancer	0.000338	0.00651	CbGeAlD
Prazosin—CYP1A1—female reproductive system—urinary bladder cancer	0.000329	0.00633	CbGeAlD
Prazosin—ABCG2—vagina—urinary bladder cancer	0.000313	0.00603	CbGeAlD
Prazosin—ABCB1—prostate gland—urinary bladder cancer	0.000313	0.00602	CbGeAlD
Prazosin—ADRA2A—female reproductive system—urinary bladder cancer	0.000306	0.0059	CbGeAlD
Prazosin—CYP1A1—vagina—urinary bladder cancer	0.000297	0.00573	CbGeAlD
Prazosin—SLC22A3—lymph node—urinary bladder cancer	0.000296	0.0057	CbGeAlD
Prazosin—ADRA2A—vagina—urinary bladder cancer	0.000277	0.00534	CbGeAlD
Prazosin—ABCB1—seminal vesicle—urinary bladder cancer	0.000265	0.0051	CbGeAlD
Prazosin—Alopecia—Gemcitabine—urinary bladder cancer	0.000233	0.00397	CcSEcCtD
Prazosin—Arthralgia—Thiotepa—urinary bladder cancer	0.000232	0.00395	CcSEcCtD
Prazosin—ABCB1—epithelium—urinary bladder cancer	0.00023	0.00443	CbGeAlD
Prazosin—Tinnitus—Cisplatin—urinary bladder cancer	0.000229	0.0039	CcSEcCtD
Prazosin—Alopecia—Fluorouracil—urinary bladder cancer	0.000229	0.0039	CcSEcCtD
Prazosin—Flushing—Cisplatin—urinary bladder cancer	0.000228	0.00388	CcSEcCtD
Prazosin—KCNH2—lymph node—urinary bladder cancer	0.000228	0.00439	CbGeAlD
Prazosin—Tachycardia—Thiotepa—urinary bladder cancer	0.000217	0.0037	CcSEcCtD
Prazosin—Alopecia—Cisplatin—urinary bladder cancer	0.000217	0.0037	CcSEcCtD
Prazosin—ABCB1—renal system—urinary bladder cancer	0.000213	0.00411	CbGeAlD
Prazosin—Ill-defined disorder—Gemcitabine—urinary bladder cancer	0.000213	0.00363	CcSEcCtD
Prazosin—Vision blurred—Fluorouracil—urinary bladder cancer	0.000213	0.00362	CcSEcCtD
Prazosin—ABCB1—urethra—urinary bladder cancer	0.000209	0.00403	CbGeAlD
Prazosin—Flushing—Etoposide—urinary bladder cancer	0.000209	0.00356	CcSEcCtD
Prazosin—Malaise—Gemcitabine—urinary bladder cancer	0.000207	0.00352	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Thiotepa—urinary bladder cancer	0.000203	0.00345	CcSEcCtD
Prazosin—ABCG2—lymph node—urinary bladder cancer	0.000203	0.0039	CbGeAlD
Prazosin—Eye pain—Epirubicin—urinary bladder cancer	0.000202	0.00344	CcSEcCtD
Prazosin—Vision blurred—Cisplatin—urinary bladder cancer	0.000202	0.00343	CcSEcCtD
Prazosin—Paraesthesia—Thiotepa—urinary bladder cancer	0.0002	0.0034	CcSEcCtD
Prazosin—Alopecia—Etoposide—urinary bladder cancer	0.000199	0.00339	CcSEcCtD
Prazosin—Ill-defined disorder—Cisplatin—urinary bladder cancer	0.000199	0.00338	CcSEcCtD
Prazosin—Somnolence—Thiotepa—urinary bladder cancer	0.000198	0.00337	CcSEcCtD
Prazosin—Arthralgia—Gemcitabine—urinary bladder cancer	0.000196	0.00333	CcSEcCtD
Prazosin—Discomfort—Gemcitabine—urinary bladder cancer	0.000193	0.00329	CcSEcCtD
Prazosin—Malaise—Cisplatin—urinary bladder cancer	0.000193	0.00328	CcSEcCtD
Prazosin—CYP1A1—lymph node—urinary bladder cancer	0.000192	0.0037	CbGeAlD
Prazosin—Fatigue—Thiotepa—urinary bladder cancer	0.000192	0.00327	CcSEcCtD
Prazosin—Pain—Thiotepa—urinary bladder cancer	0.000191	0.00324	CcSEcCtD
Prazosin—Constipation—Thiotepa—urinary bladder cancer	0.000191	0.00324	CcSEcCtD
Prazosin—Discomfort—Fluorouracil—urinary bladder cancer	0.00019	0.00323	CcSEcCtD
Prazosin—Oedema—Gemcitabine—urinary bladder cancer	0.000187	0.00319	CcSEcCtD
Prazosin—Eye pain—Doxorubicin—urinary bladder cancer	0.000187	0.00318	CcSEcCtD
Prazosin—Oedema—Fluorouracil—urinary bladder cancer	0.000184	0.00314	CcSEcCtD
Prazosin—Feeling abnormal—Thiotepa—urinary bladder cancer	0.000184	0.00312	CcSEcCtD
Prazosin—Ill-defined disorder—Etoposide—urinary bladder cancer	0.000182	0.0031	CcSEcCtD
Prazosin—Hyperhidrosis—Gemcitabine—urinary bladder cancer	0.000181	0.00308	CcSEcCtD
Prazosin—Discomfort—Cisplatin—urinary bladder cancer	0.00018	0.00306	CcSEcCtD
Prazosin—Tachycardia—Fluorouracil—urinary bladder cancer	0.00018	0.00306	CcSEcCtD
Prazosin—ADRA2A—lymph node—urinary bladder cancer	0.000179	0.00345	CbGeAlD
Prazosin—Urticaria—Thiotepa—urinary bladder cancer	0.000177	0.00301	CcSEcCtD
Prazosin—Malaise—Etoposide—urinary bladder cancer	0.000177	0.00301	CcSEcCtD
Prazosin—Vertigo—Etoposide—urinary bladder cancer	0.000176	0.003	CcSEcCtD
Prazosin—Body temperature increased—Thiotepa—urinary bladder cancer	0.000176	0.003	CcSEcCtD
Prazosin—Oedema—Cisplatin—urinary bladder cancer	0.000175	0.00297	CcSEcCtD
Prazosin—Loss of consciousness—Etoposide—urinary bladder cancer	0.000172	0.00293	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Gemcitabine—urinary bladder cancer	0.000171	0.00291	CcSEcCtD
Prazosin—ABCB1—female reproductive system—urinary bladder cancer	0.000171	0.00329	CbGeAlD
Prazosin—Tachycardia—Cisplatin—urinary bladder cancer	0.000171	0.0029	CcSEcCtD
Prazosin—Insomnia—Gemcitabine—urinary bladder cancer	0.00017	0.00288	CcSEcCtD
Prazosin—Hyperhidrosis—Cisplatin—urinary bladder cancer	0.000169	0.00287	CcSEcCtD
Prazosin—Paraesthesia—Gemcitabine—urinary bladder cancer	0.000168	0.00286	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Fluorouracil—urinary bladder cancer	0.000168	0.00286	CcSEcCtD
Prazosin—Dyspnoea—Gemcitabine—urinary bladder cancer	0.000167	0.00284	CcSEcCtD
Prazosin—Orthostatic hypotension—Epirubicin—urinary bladder cancer	0.000167	0.00284	CcSEcCtD
Prazosin—Insomnia—Fluorouracil—urinary bladder cancer	0.000167	0.00284	CcSEcCtD
Prazosin—Somnolence—Gemcitabine—urinary bladder cancer	0.000167	0.00283	CcSEcCtD
Prazosin—Paraesthesia—Fluorouracil—urinary bladder cancer	0.000166	0.00282	CcSEcCtD
Prazosin—Pancreatitis—Methotrexate—urinary bladder cancer	0.000165	0.00281	CcSEcCtD
Prazosin—Discomfort—Etoposide—urinary bladder cancer	0.000165	0.00281	CcSEcCtD
Prazosin—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000164	0.0028	CcSEcCtD
Prazosin—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000164	0.00279	CcSEcCtD
Prazosin—Somnolence—Fluorouracil—urinary bladder cancer	0.000164	0.00279	CcSEcCtD
Prazosin—Abdominal discomfort—Methotrexate—urinary bladder cancer	0.000162	0.00275	CcSEcCtD
Prazosin—Fatigue—Gemcitabine—urinary bladder cancer	0.000162	0.00275	CcSEcCtD
Prazosin—Constipation—Gemcitabine—urinary bladder cancer	0.00016	0.00273	CcSEcCtD
Prazosin—Pain—Gemcitabine—urinary bladder cancer	0.00016	0.00273	CcSEcCtD
Prazosin—Asthenia—Thiotepa—urinary bladder cancer	0.00016	0.00272	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Cisplatin—urinary bladder cancer	0.000159	0.00271	CcSEcCtD
Prazosin—Pruritus—Thiotepa—urinary bladder cancer	0.000158	0.00268	CcSEcCtD
Prazosin—Pain—Fluorouracil—urinary bladder cancer	0.000158	0.00268	CcSEcCtD
Prazosin—Paraesthesia—Cisplatin—urinary bladder cancer	0.000157	0.00267	CcSEcCtD
Prazosin—Tachycardia—Etoposide—urinary bladder cancer	0.000156	0.00266	CcSEcCtD
Prazosin—Dyspnoea—Cisplatin—urinary bladder cancer	0.000156	0.00265	CcSEcCtD
Prazosin—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000155	0.00264	CcSEcCtD
Prazosin—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000155	0.00263	CcSEcCtD
Prazosin—Pancreatitis—Epirubicin—urinary bladder cancer	0.000155	0.00263	CcSEcCtD
Prazosin—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000154	0.00263	CcSEcCtD
Prazosin—ABCB1—vagina—urinary bladder cancer	0.000154	0.00297	CbGeAlD
Prazosin—Orthostatic hypotension—Doxorubicin—urinary bladder cancer	0.000154	0.00262	CcSEcCtD
Prazosin—Angina pectoris—Epirubicin—urinary bladder cancer	0.000154	0.00261	CcSEcCtD
Prazosin—Diarrhoea—Thiotepa—urinary bladder cancer	0.000152	0.00259	CcSEcCtD
Prazosin—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000152	0.00258	CcSEcCtD
Prazosin—Drowsiness—Methotrexate—urinary bladder cancer	0.00015	0.00256	CcSEcCtD
Prazosin—Pain—Cisplatin—urinary bladder cancer	0.000149	0.00254	CcSEcCtD
Prazosin—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000148	0.00252	CcSEcCtD
Prazosin—Dizziness—Thiotepa—urinary bladder cancer	0.000147	0.00251	CcSEcCtD
Prazosin—Urticaria—Fluorouracil—urinary bladder cancer	0.000146	0.00249	CcSEcCtD
Prazosin—Pollakiuria—Epirubicin—urinary bladder cancer	0.000146	0.00248	CcSEcCtD
Prazosin—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000146	0.00248	CcSEcCtD
Prazosin—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000144	0.00245	CcSEcCtD
Prazosin—Paraesthesia—Etoposide—urinary bladder cancer	0.000144	0.00245	CcSEcCtD
Prazosin—Pancreatitis—Doxorubicin—urinary bladder cancer	0.000143	0.00244	CcSEcCtD
Prazosin—Dyspnoea—Etoposide—urinary bladder cancer	0.000143	0.00243	CcSEcCtD
Prazosin—Somnolence—Etoposide—urinary bladder cancer	0.000142	0.00242	CcSEcCtD
Prazosin—Angina pectoris—Doxorubicin—urinary bladder cancer	0.000142	0.00242	CcSEcCtD
Prazosin—Epistaxis—Methotrexate—urinary bladder cancer	0.000142	0.00241	CcSEcCtD
Prazosin—Vomiting—Thiotepa—urinary bladder cancer	0.000142	0.00241	CcSEcCtD
Prazosin—Drowsiness—Epirubicin—urinary bladder cancer	0.000141	0.00239	CcSEcCtD
Prazosin—Rash—Thiotepa—urinary bladder cancer	0.000141	0.00239	CcSEcCtD
Prazosin—Dermatitis—Thiotepa—urinary bladder cancer	0.00014	0.00239	CcSEcCtD
Prazosin—Headache—Thiotepa—urinary bladder cancer	0.00014	0.00237	CcSEcCtD
Prazosin—Body temperature increased—Cisplatin—urinary bladder cancer	0.000138	0.00235	CcSEcCtD
Prazosin—Fatigue—Etoposide—urinary bladder cancer	0.000138	0.00235	CcSEcCtD
Prazosin—Constipation—Etoposide—urinary bladder cancer	0.000137	0.00233	CcSEcCtD
Prazosin—Pain—Etoposide—urinary bladder cancer	0.000137	0.00233	CcSEcCtD
Prazosin—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000136	0.00231	CcSEcCtD
Prazosin—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000135	0.00229	CcSEcCtD
Prazosin—Asthenia—Gemcitabine—urinary bladder cancer	0.000134	0.00229	CcSEcCtD
Prazosin—Epistaxis—Epirubicin—urinary bladder cancer	0.000133	0.00226	CcSEcCtD
Prazosin—Pruritus—Gemcitabine—urinary bladder cancer	0.000133	0.00226	CcSEcCtD
Prazosin—Nausea—Thiotepa—urinary bladder cancer	0.000132	0.00225	CcSEcCtD
Prazosin—Feeling abnormal—Etoposide—urinary bladder cancer	0.000132	0.00224	CcSEcCtD
Prazosin—Pruritus—Fluorouracil—urinary bladder cancer	0.00013	0.00222	CcSEcCtD
Prazosin—Drowsiness—Doxorubicin—urinary bladder cancer	0.00013	0.00221	CcSEcCtD
Prazosin—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000129	0.00219	CcSEcCtD
Prazosin—Bradycardia—Epirubicin—urinary bladder cancer	0.000129	0.00219	CcSEcCtD
Prazosin—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000128	0.00218	CcSEcCtD
Prazosin—Urticaria—Etoposide—urinary bladder cancer	0.000127	0.00216	CcSEcCtD
Prazosin—Body temperature increased—Etoposide—urinary bladder cancer	0.000127	0.00215	CcSEcCtD
Prazosin—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000126	0.00215	CcSEcCtD
Prazosin—Tinnitus—Methotrexate—urinary bladder cancer	0.000126	0.00214	CcSEcCtD
Prazosin—Asthenia—Cisplatin—urinary bladder cancer	0.000125	0.00213	CcSEcCtD
Prazosin—Epistaxis—Doxorubicin—urinary bladder cancer	0.000123	0.00209	CcSEcCtD
Prazosin—Dizziness—Fluorouracil—urinary bladder cancer	0.000122	0.00207	CcSEcCtD
Prazosin—Diarrhoea—Cisplatin—urinary bladder cancer	0.00012	0.00203	CcSEcCtD
Prazosin—Alopecia—Methotrexate—urinary bladder cancer	0.000119	0.00203	CcSEcCtD
Prazosin—Vomiting—Gemcitabine—urinary bladder cancer	0.000119	0.00203	CcSEcCtD
Prazosin—Bradycardia—Doxorubicin—urinary bladder cancer	0.000119	0.00202	CcSEcCtD
Prazosin—Rash—Gemcitabine—urinary bladder cancer	0.000118	0.00201	CcSEcCtD
Prazosin—Dermatitis—Gemcitabine—urinary bladder cancer	0.000118	0.00201	CcSEcCtD
Prazosin—Hypersensitivity—Etoposide—urinary bladder cancer	0.000118	0.00201	CcSEcCtD
Prazosin—Tinnitus—Epirubicin—urinary bladder cancer	0.000118	0.002	CcSEcCtD
Prazosin—Headache—Gemcitabine—urinary bladder cancer	0.000117	0.002	CcSEcCtD
Prazosin—Flushing—Epirubicin—urinary bladder cancer	0.000117	0.00199	CcSEcCtD
Prazosin—Vomiting—Fluorouracil—urinary bladder cancer	0.000117	0.00199	CcSEcCtD
Prazosin—Rash—Fluorouracil—urinary bladder cancer	0.000116	0.00198	CcSEcCtD
Prazosin—Dermatitis—Fluorouracil—urinary bladder cancer	0.000116	0.00198	CcSEcCtD
Prazosin—Headache—Fluorouracil—urinary bladder cancer	0.000115	0.00196	CcSEcCtD
Prazosin—Asthenia—Etoposide—urinary bladder cancer	0.000115	0.00195	CcSEcCtD
Prazosin—Pruritus—Etoposide—urinary bladder cancer	0.000113	0.00193	CcSEcCtD
Prazosin—Alopecia—Epirubicin—urinary bladder cancer	0.000112	0.0019	CcSEcCtD
Prazosin—Nausea—Gemcitabine—urinary bladder cancer	0.000111	0.00189	CcSEcCtD
Prazosin—Vomiting—Cisplatin—urinary bladder cancer	0.000111	0.00189	CcSEcCtD
Prazosin—Vision blurred—Methotrexate—urinary bladder cancer	0.000111	0.00188	CcSEcCtD
Prazosin—Rash—Cisplatin—urinary bladder cancer	0.00011	0.00187	CcSEcCtD
Prazosin—Dermatitis—Cisplatin—urinary bladder cancer	0.00011	0.00187	CcSEcCtD
Prazosin—Diarrhoea—Etoposide—urinary bladder cancer	0.00011	0.00186	CcSEcCtD
Prazosin—Nausea—Fluorouracil—urinary bladder cancer	0.000109	0.00186	CcSEcCtD
Prazosin—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000109	0.00185	CcSEcCtD
Prazosin—Tinnitus—Doxorubicin—urinary bladder cancer	0.000109	0.00185	CcSEcCtD
Prazosin—Flushing—Doxorubicin—urinary bladder cancer	0.000108	0.00184	CcSEcCtD
Prazosin—Tension—Epirubicin—urinary bladder cancer	0.000108	0.00184	CcSEcCtD
Prazosin—Nervousness—Epirubicin—urinary bladder cancer	0.000107	0.00182	CcSEcCtD
Prazosin—Malaise—Methotrexate—urinary bladder cancer	0.000106	0.0018	CcSEcCtD
Prazosin—Dizziness—Etoposide—urinary bladder cancer	0.000106	0.0018	CcSEcCtD
Prazosin—Vertigo—Methotrexate—urinary bladder cancer	0.000106	0.0018	CcSEcCtD
Prazosin—Nausea—Cisplatin—urinary bladder cancer	0.000104	0.00177	CcSEcCtD
Prazosin—Vision blurred—Epirubicin—urinary bladder cancer	0.000104	0.00176	CcSEcCtD
Prazosin—Alopecia—Doxorubicin—urinary bladder cancer	0.000103	0.00176	CcSEcCtD
Prazosin—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000102	0.00174	CcSEcCtD
Prazosin—Vomiting—Etoposide—urinary bladder cancer	0.000102	0.00173	CcSEcCtD
Prazosin—Rash—Etoposide—urinary bladder cancer	0.000101	0.00172	CcSEcCtD
Prazosin—Dermatitis—Etoposide—urinary bladder cancer	0.000101	0.00172	CcSEcCtD
Prazosin—Headache—Etoposide—urinary bladder cancer	0.0001	0.00171	CcSEcCtD
Prazosin—Arthralgia—Methotrexate—urinary bladder cancer	0.0001	0.0017	CcSEcCtD
Prazosin—ABCB1—lymph node—urinary bladder cancer	9.99e-05	0.00192	CbGeAlD
Prazosin—Tension—Doxorubicin—urinary bladder cancer	9.98e-05	0.0017	CcSEcCtD
Prazosin—Malaise—Epirubicin—urinary bladder cancer	9.91e-05	0.00169	CcSEcCtD
Prazosin—Discomfort—Methotrexate—urinary bladder cancer	9.88e-05	0.00168	CcSEcCtD
Prazosin—Nervousness—Doxorubicin—urinary bladder cancer	9.88e-05	0.00168	CcSEcCtD
Prazosin—Vertigo—Epirubicin—urinary bladder cancer	9.88e-05	0.00168	CcSEcCtD
Prazosin—Syncope—Epirubicin—urinary bladder cancer	9.86e-05	0.00168	CcSEcCtD
Prazosin—Palpitations—Epirubicin—urinary bladder cancer	9.72e-05	0.00165	CcSEcCtD
Prazosin—Loss of consciousness—Epirubicin—urinary bladder cancer	9.66e-05	0.00164	CcSEcCtD
Prazosin—Vision blurred—Doxorubicin—urinary bladder cancer	9.59e-05	0.00163	CcSEcCtD
Prazosin—Nausea—Etoposide—urinary bladder cancer	9.51e-05	0.00162	CcSEcCtD
Prazosin—Ill-defined disorder—Doxorubicin—urinary bladder cancer	9.44e-05	0.00161	CcSEcCtD
Prazosin—Arthralgia—Epirubicin—urinary bladder cancer	9.36e-05	0.00159	CcSEcCtD
Prazosin—Hyperhidrosis—Methotrexate—urinary bladder cancer	9.27e-05	0.00158	CcSEcCtD
Prazosin—Discomfort—Epirubicin—urinary bladder cancer	9.25e-05	0.00157	CcSEcCtD
Prazosin—Malaise—Doxorubicin—urinary bladder cancer	9.17e-05	0.00156	CcSEcCtD
Prazosin—Dry mouth—Epirubicin—urinary bladder cancer	9.15e-05	0.00156	CcSEcCtD
Prazosin—Vertigo—Doxorubicin—urinary bladder cancer	9.14e-05	0.00155	CcSEcCtD
Prazosin—Syncope—Doxorubicin—urinary bladder cancer	9.12e-05	0.00155	CcSEcCtD
Prazosin—Palpitations—Doxorubicin—urinary bladder cancer	8.99e-05	0.00153	CcSEcCtD
Prazosin—Oedema—Epirubicin—urinary bladder cancer	8.97e-05	0.00153	CcSEcCtD
Prazosin—Loss of consciousness—Doxorubicin—urinary bladder cancer	8.94e-05	0.00152	CcSEcCtD
Prazosin—Shock—Epirubicin—urinary bladder cancer	8.83e-05	0.0015	CcSEcCtD
Prazosin—Tachycardia—Epirubicin—urinary bladder cancer	8.76e-05	0.00149	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	8.74e-05	0.00149	CcSEcCtD
Prazosin—Hyperhidrosis—Epirubicin—urinary bladder cancer	8.67e-05	0.00148	CcSEcCtD
Prazosin—Insomnia—Methotrexate—urinary bladder cancer	8.67e-05	0.00148	CcSEcCtD
Prazosin—Arthralgia—Doxorubicin—urinary bladder cancer	8.66e-05	0.00147	CcSEcCtD
Prazosin—Paraesthesia—Methotrexate—urinary bladder cancer	8.61e-05	0.00146	CcSEcCtD
Prazosin—Discomfort—Doxorubicin—urinary bladder cancer	8.56e-05	0.00146	CcSEcCtD
Prazosin—Dyspnoea—Methotrexate—urinary bladder cancer	8.55e-05	0.00145	CcSEcCtD
Prazosin—Somnolence—Methotrexate—urinary bladder cancer	8.52e-05	0.00145	CcSEcCtD
Prazosin—Dry mouth—Doxorubicin—urinary bladder cancer	8.47e-05	0.00144	CcSEcCtD
Prazosin—Oedema—Doxorubicin—urinary bladder cancer	8.3e-05	0.00141	CcSEcCtD
Prazosin—Fatigue—Methotrexate—urinary bladder cancer	8.27e-05	0.00141	CcSEcCtD
Prazosin—Pain—Methotrexate—urinary bladder cancer	8.2e-05	0.00139	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	8.17e-05	0.00139	CcSEcCtD
Prazosin—Shock—Doxorubicin—urinary bladder cancer	8.17e-05	0.00139	CcSEcCtD
Prazosin—Insomnia—Epirubicin—urinary bladder cancer	8.12e-05	0.00138	CcSEcCtD
Prazosin—Tachycardia—Doxorubicin—urinary bladder cancer	8.1e-05	0.00138	CcSEcCtD
Prazosin—Paraesthesia—Epirubicin—urinary bladder cancer	8.06e-05	0.00137	CcSEcCtD
Prazosin—Hyperhidrosis—Doxorubicin—urinary bladder cancer	8.03e-05	0.00137	CcSEcCtD
Prazosin—Dyspnoea—Epirubicin—urinary bladder cancer	8e-05	0.00136	CcSEcCtD
Prazosin—Somnolence—Epirubicin—urinary bladder cancer	7.98e-05	0.00136	CcSEcCtD
Prazosin—Feeling abnormal—Methotrexate—urinary bladder cancer	7.9e-05	0.00134	CcSEcCtD
Prazosin—Fatigue—Epirubicin—urinary bladder cancer	7.74e-05	0.00132	CcSEcCtD
Prazosin—Pain—Epirubicin—urinary bladder cancer	7.67e-05	0.00131	CcSEcCtD
Prazosin—Constipation—Epirubicin—urinary bladder cancer	7.67e-05	0.00131	CcSEcCtD
Prazosin—Urticaria—Methotrexate—urinary bladder cancer	7.62e-05	0.0013	CcSEcCtD
Prazosin—Body temperature increased—Methotrexate—urinary bladder cancer	7.58e-05	0.00129	CcSEcCtD
Prazosin—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	7.56e-05	0.00129	CcSEcCtD
Prazosin—Insomnia—Doxorubicin—urinary bladder cancer	7.51e-05	0.00128	CcSEcCtD
Prazosin—Paraesthesia—Doxorubicin—urinary bladder cancer	7.45e-05	0.00127	CcSEcCtD
Prazosin—Dyspnoea—Doxorubicin—urinary bladder cancer	7.4e-05	0.00126	CcSEcCtD
Prazosin—Feeling abnormal—Epirubicin—urinary bladder cancer	7.39e-05	0.00126	CcSEcCtD
Prazosin—Somnolence—Doxorubicin—urinary bladder cancer	7.38e-05	0.00126	CcSEcCtD
Prazosin—Fatigue—Doxorubicin—urinary bladder cancer	7.16e-05	0.00122	CcSEcCtD
Prazosin—Urticaria—Epirubicin—urinary bladder cancer	7.13e-05	0.00121	CcSEcCtD
Prazosin—Pain—Doxorubicin—urinary bladder cancer	7.1e-05	0.00121	CcSEcCtD
Prazosin—Constipation—Doxorubicin—urinary bladder cancer	7.1e-05	0.00121	CcSEcCtD
Prazosin—Body temperature increased—Epirubicin—urinary bladder cancer	7.09e-05	0.00121	CcSEcCtD
Prazosin—Hypersensitivity—Methotrexate—urinary bladder cancer	7.06e-05	0.0012	CcSEcCtD
Prazosin—Asthenia—Methotrexate—urinary bladder cancer	6.88e-05	0.00117	CcSEcCtD
Prazosin—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.84e-05	0.00116	CcSEcCtD
Prazosin—Pruritus—Methotrexate—urinary bladder cancer	6.78e-05	0.00115	CcSEcCtD
Prazosin—Hypersensitivity—Epirubicin—urinary bladder cancer	6.61e-05	0.00112	CcSEcCtD
Prazosin—Urticaria—Doxorubicin—urinary bladder cancer	6.6e-05	0.00112	CcSEcCtD
Prazosin—Body temperature increased—Doxorubicin—urinary bladder cancer	6.56e-05	0.00112	CcSEcCtD
Prazosin—Diarrhoea—Methotrexate—urinary bladder cancer	6.56e-05	0.00112	CcSEcCtD
Prazosin—Asthenia—Epirubicin—urinary bladder cancer	6.44e-05	0.0011	CcSEcCtD
Prazosin—Pruritus—Epirubicin—urinary bladder cancer	6.35e-05	0.00108	CcSEcCtD
Prazosin—Dizziness—Methotrexate—urinary bladder cancer	6.34e-05	0.00108	CcSEcCtD
Prazosin—Diarrhoea—Epirubicin—urinary bladder cancer	6.14e-05	0.00104	CcSEcCtD
Prazosin—Hypersensitivity—Doxorubicin—urinary bladder cancer	6.12e-05	0.00104	CcSEcCtD
Prazosin—Vomiting—Methotrexate—urinary bladder cancer	6.1e-05	0.00104	CcSEcCtD
Prazosin—Rash—Methotrexate—urinary bladder cancer	6.05e-05	0.00103	CcSEcCtD
Prazosin—Dermatitis—Methotrexate—urinary bladder cancer	6.04e-05	0.00103	CcSEcCtD
Prazosin—Headache—Methotrexate—urinary bladder cancer	6.01e-05	0.00102	CcSEcCtD
Prazosin—Asthenia—Doxorubicin—urinary bladder cancer	5.96e-05	0.00101	CcSEcCtD
Prazosin—Dizziness—Epirubicin—urinary bladder cancer	5.93e-05	0.00101	CcSEcCtD
Prazosin—Pruritus—Doxorubicin—urinary bladder cancer	5.87e-05	0.000999	CcSEcCtD
Prazosin—Vomiting—Epirubicin—urinary bladder cancer	5.7e-05	0.000971	CcSEcCtD
Prazosin—Nausea—Methotrexate—urinary bladder cancer	5.7e-05	0.000969	CcSEcCtD
Prazosin—Diarrhoea—Doxorubicin—urinary bladder cancer	5.68e-05	0.000966	CcSEcCtD
Prazosin—Rash—Epirubicin—urinary bladder cancer	5.66e-05	0.000962	CcSEcCtD
Prazosin—Dermatitis—Epirubicin—urinary bladder cancer	5.65e-05	0.000962	CcSEcCtD
Prazosin—Headache—Epirubicin—urinary bladder cancer	5.62e-05	0.000956	CcSEcCtD
Prazosin—Dizziness—Doxorubicin—urinary bladder cancer	5.49e-05	0.000934	CcSEcCtD
Prazosin—Nausea—Epirubicin—urinary bladder cancer	5.33e-05	0.000907	CcSEcCtD
Prazosin—Vomiting—Doxorubicin—urinary bladder cancer	5.28e-05	0.000898	CcSEcCtD
Prazosin—Rash—Doxorubicin—urinary bladder cancer	5.23e-05	0.000891	CcSEcCtD
Prazosin—Dermatitis—Doxorubicin—urinary bladder cancer	5.23e-05	0.00089	CcSEcCtD
Prazosin—Headache—Doxorubicin—urinary bladder cancer	5.2e-05	0.000885	CcSEcCtD
Prazosin—Nausea—Doxorubicin—urinary bladder cancer	4.93e-05	0.000839	CcSEcCtD
Prazosin—HTR1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	6.97e-06	0.000149	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—IL2—urinary bladder cancer	6.94e-06	0.000149	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TERT—urinary bladder cancer	6.92e-06	0.000148	CbGpPWpGaD
Prazosin—ADRA2B—GPCR downstream signaling—IL2—urinary bladder cancer	6.9e-06	0.000148	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—RHOA—urinary bladder cancer	6.87e-06	0.000147	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—NCOR1—urinary bladder cancer	6.84e-06	0.000147	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—RHOA—urinary bladder cancer	6.72e-06	0.000144	CbGpPWpGaD
Prazosin—ADRA2B—Hemostasis—HRAS—urinary bladder cancer	6.71e-06	0.000144	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—MTHFR—urinary bladder cancer	6.71e-06	0.000144	CbGpPWpGaD
Prazosin—HTR1A—GPCR downstream signaling—IL2—urinary bladder cancer	6.66e-06	0.000143	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—CXCL8—urinary bladder cancer	6.64e-06	0.000142	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—CXCL8—urinary bladder cancer	6.56e-06	0.000141	CbGpPWpGaD
Prazosin—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	6.54e-06	0.00014	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—NCOR1—urinary bladder cancer	6.52e-06	0.00014	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—TYMS—urinary bladder cancer	6.51e-06	0.000139	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—S100B—urinary bladder cancer	6.44e-06	0.000138	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—NCOR1—urinary bladder cancer	6.43e-06	0.000138	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—GSTM1—urinary bladder cancer	6.43e-06	0.000138	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—PTEN—urinary bladder cancer	6.38e-06	0.000137	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—FGFR3—urinary bladder cancer	6.35e-06	0.000136	CbGpPWpGaD
Prazosin—ADRA1B—GPCR downstream signaling—IL2—urinary bladder cancer	6.35e-06	0.000136	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—CXCL8—urinary bladder cancer	6.33e-06	0.000136	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CREBBP—urinary bladder cancer	6.32e-06	0.000135	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—IL2—urinary bladder cancer	6.27e-06	0.000134	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TERT—urinary bladder cancer	6.25e-06	0.000134	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—RHOA—urinary bladder cancer	6.24e-06	0.000134	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IGF1—urinary bladder cancer	6.24e-06	0.000134	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—EGFR—urinary bladder cancer	6.21e-06	0.000133	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—ESR1—urinary bladder cancer	6.17e-06	0.000132	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—GPX1—urinary bladder cancer	6.16e-06	0.000132	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.15e-06	0.000132	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—RHOA—urinary bladder cancer	6.1e-06	0.000131	CbGpPWpGaD
Prazosin—SLC22A3—Metabolism—EP300—urinary bladder cancer	6.09e-06	0.00013	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—GSTP1—urinary bladder cancer	6.06e-06	0.00013	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—IL2—urinary bladder cancer	6.05e-06	0.00013	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—ERCC2—urinary bladder cancer	6.05e-06	0.00013	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—CXCL8—urinary bladder cancer	6.03e-06	0.000129	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TERT—urinary bladder cancer	6.03e-06	0.000129	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—KRAS—urinary bladder cancer	5.99e-06	0.000128	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—S100B—urinary bladder cancer	5.98e-06	0.000128	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.9e-06	0.000126	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PPARG—urinary bladder cancer	5.9e-06	0.000126	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—KRAS—urinary bladder cancer	5.86e-06	0.000126	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	5.86e-06	0.000126	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PPARG—urinary bladder cancer	5.83e-06	0.000125	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—NQO1—urinary bladder cancer	5.8e-06	0.000124	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—NCOR1—urinary bladder cancer	5.79e-06	0.000124	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—IL2—urinary bladder cancer	5.76e-06	0.000123	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TERT—urinary bladder cancer	5.74e-06	0.000123	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—FGFR3—urinary bladder cancer	5.73e-06	0.000123	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—RHOA—urinary bladder cancer	5.71e-06	0.000122	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—MTHFR—urinary bladder cancer	5.68e-06	0.000122	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—RHOA—urinary bladder cancer	5.67e-06	0.000121	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—CREBBP—urinary bladder cancer	5.66e-06	0.000121	CbGpPWpGaD
Prazosin—ADRA1A—GPCR downstream signaling—IL2—urinary bladder cancer	5.64e-06	0.000121	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—TYMS—urinary bladder cancer	5.63e-06	0.000121	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—CREBBP—urinary bladder cancer	5.6e-06	0.00012	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—GSTM1—urinary bladder cancer	5.57e-06	0.000119	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—NCOR1—urinary bladder cancer	5.57e-06	0.000119	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—ESR1—urinary bladder cancer	5.57e-06	0.000119	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—FGFR3—urinary bladder cancer	5.53e-06	0.000119	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	5.48e-06	0.000117	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PPARG—urinary bladder cancer	5.44e-06	0.000116	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CREBBP—urinary bladder cancer	5.41e-06	0.000116	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—NCOR1—urinary bladder cancer	5.38e-06	0.000115	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—ESR1—urinary bladder cancer	5.37e-06	0.000115	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—CXCL8—urinary bladder cancer	5.36e-06	0.000115	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IGF1—urinary bladder cancer	5.34e-06	0.000114	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—GPX1—urinary bladder cancer	5.33e-06	0.000114	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—TP53—urinary bladder cancer	5.32e-06	0.000114	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—EGFR—urinary bladder cancer	5.31e-06	0.000114	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—ERBB2—urinary bladder cancer	5.29e-06	0.000113	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—FGFR3—urinary bladder cancer	5.27e-06	0.000113	CbGpPWpGaD
Prazosin—ADRA2A—GPCR downstream signaling—IL2—urinary bladder cancer	5.24e-06	0.000112	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—ERCC2—urinary bladder cancer	5.24e-06	0.000112	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—CREBBP—urinary bladder cancer	5.22e-06	0.000112	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—IL2—urinary bladder cancer	5.12e-06	0.00011	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—ESR1—urinary bladder cancer	5.12e-06	0.00011	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TERT—urinary bladder cancer	5.1e-06	0.000109	CbGpPWpGaD
Prazosin—ADRA2A—Hemostasis—HRAS—urinary bladder cancer	5.09e-06	0.000109	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—KRAS—urinary bladder cancer	5.02e-06	0.000107	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CXCL8—urinary bladder cancer	5.02e-06	0.000107	CbGpPWpGaD
Prazosin—HTR1D—Signaling by GPCR—HRAS—urinary bladder cancer	4.98e-06	0.000107	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—CXCL8—urinary bladder cancer	4.98e-06	0.000107	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—MTHFR—urinary bladder cancer	4.92e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—RHOA—urinary bladder cancer	4.89e-06	0.000105	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CREBBP—urinary bladder cancer	4.88e-06	0.000105	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—GSTP1—urinary bladder cancer	4.84e-06	0.000104	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IGF1—urinary bladder cancer	4.82e-06	0.000103	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—EGFR—urinary bladder cancer	4.8e-06	0.000103	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—IL2—urinary bladder cancer	4.79e-06	0.000103	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—IL2—urinary bladder cancer	4.76e-06	0.000102	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TERT—urinary bladder cancer	4.74e-06	0.000102	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CREBBP—urinary bladder cancer	4.71e-06	0.000101	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—FGFR3—urinary bladder cancer	4.68e-06	0.0001	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CCND1—urinary bladder cancer	4.67e-06	0.0001	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IGF1—urinary bladder cancer	4.65e-06	9.96e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PTGS2—urinary bladder cancer	4.64e-06	9.93e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—EGFR—urinary bladder cancer	4.63e-06	9.91e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PPARG—urinary bladder cancer	4.61e-06	9.87e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTGS2—urinary bladder cancer	4.59e-06	9.83e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—ESR1—urinary bladder cancer	4.55e-06	9.74e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MMP9—urinary bladder cancer	4.54e-06	9.72e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—KRAS—urinary bladder cancer	4.53e-06	9.7e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—ERBB2—urinary bladder cancer	4.53e-06	9.7e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—CDKN1A—urinary bladder cancer	4.52e-06	9.68e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—PTEN—urinary bladder cancer	4.51e-06	9.66e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—TYMS—urinary bladder cancer	4.5e-06	9.64e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CREBBP—urinary bladder cancer	4.49e-06	9.61e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—NCOR1—urinary bladder cancer	4.45e-06	9.53e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—GSTM1—urinary bladder cancer	4.45e-06	9.53e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IGF1—urinary bladder cancer	4.43e-06	9.49e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—CREBBP—urinary bladder cancer	4.43e-06	9.48e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—RHOA—urinary bladder cancer	4.41e-06	9.46e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—EGFR—urinary bladder cancer	4.41e-06	9.44e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—KRAS—urinary bladder cancer	4.37e-06	9.37e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—FGFR3—urinary bladder cancer	4.35e-06	9.32e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—EP300—urinary bladder cancer	4.3e-06	9.21e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CXCL8—urinary bladder cancer	4.29e-06	9.19e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTGS2—urinary bladder cancer	4.28e-06	9.16e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling by GPCR—HRAS—urinary bladder cancer	4.26e-06	9.13e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—RHOA—urinary bladder cancer	4.26e-06	9.13e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—GPX1—urinary bladder cancer	4.26e-06	9.12e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ESR1—urinary bladder cancer	4.22e-06	9.05e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—SRC—urinary bladder cancer	4.18e-06	8.96e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—ERCC2—urinary bladder cancer	4.18e-06	8.96e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—KRAS—urinary bladder cancer	4.16e-06	8.92e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—IL2—urinary bladder cancer	4.1e-06	8.79e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—ERBB2—urinary bladder cancer	4.09e-06	8.75e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—RHOA—urinary bladder cancer	4.06e-06	8.69e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—PTEN—urinary bladder cancer	4.04e-06	8.66e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—PTEN—urinary bladder cancer	4e-06	8.57e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CCND1—urinary bladder cancer	4e-06	8.57e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PPARG—urinary bladder cancer	3.99e-06	8.55e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CREBBP—urinary bladder cancer	3.98e-06	8.54e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—ERBB2—urinary bladder cancer	3.95e-06	8.45e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IGF1—urinary bladder cancer	3.94e-06	8.43e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—MTHFR—urinary bladder cancer	3.93e-06	8.42e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—EGFR—urinary bladder cancer	3.92e-06	8.39e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MMP9—urinary bladder cancer	3.88e-06	8.32e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CXCL8—urinary bladder cancer	3.88e-06	8.3e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—CDKN1A—urinary bladder cancer	3.87e-06	8.29e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—PTEN—urinary bladder cancer	3.86e-06	8.27e-05	CbGpPWpGaD
Prazosin—ABCG2—Metabolism—EP300—urinary bladder cancer	3.86e-06	8.26e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling by GPCR—HRAS—urinary bladder cancer	3.85e-06	8.25e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—CREBBP—urinary bladder cancer	3.83e-06	8.21e-05	CbGpPWpGaD
Prazosin—SLC22A2—Metabolism—EP300—urinary bladder cancer	3.82e-06	8.18e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—ERBB2—urinary bladder cancer	3.76e-06	8.05e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—MYC—urinary bladder cancer	3.75e-06	8.03e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CXCL8—urinary bladder cancer	3.74e-06	8.01e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—PTEN—urinary bladder cancer	3.73e-06	7.99e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling by GPCR—HRAS—urinary bladder cancer	3.72e-06	7.96e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—IL2—urinary bladder cancer	3.7e-06	7.93e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CREBBP—urinary bladder cancer	3.7e-06	7.93e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—KRAS—urinary bladder cancer	3.7e-06	7.92e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—EP300—urinary bladder cancer	3.68e-06	7.88e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—EGFR—urinary bladder cancer	3.67e-06	7.85e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IGF1—urinary bladder cancer	3.66e-06	7.83e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—EGFR—urinary bladder cancer	3.64e-06	7.79e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTGS2—urinary bladder cancer	3.63e-06	7.77e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CCND1—urinary bladder cancer	3.61e-06	7.73e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—RHOA—urinary bladder cancer	3.6e-06	7.72e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—SRC—urinary bladder cancer	3.58e-06	7.67e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—IL2—urinary bladder cancer	3.58e-06	7.66e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CXCL8—urinary bladder cancer	3.56e-06	7.63e-05	CbGpPWpGaD
Prazosin—SLC22A1—Metabolism—EP300—urinary bladder cancer	3.56e-06	7.62e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling by GPCR—HRAS—urinary bladder cancer	3.54e-06	7.58e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MMP9—urinary bladder cancer	3.51e-06	7.51e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—CDKN1A—urinary bladder cancer	3.49e-06	7.48e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CCND1—urinary bladder cancer	3.49e-06	7.47e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—PTEN—urinary bladder cancer	3.48e-06	7.46e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—KRAS—urinary bladder cancer	3.46e-06	7.42e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—KRAS—urinary bladder cancer	3.44e-06	7.36e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—IL2—urinary bladder cancer	3.4e-06	7.29e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MMP9—urinary bladder cancer	3.38e-06	7.25e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—CDKN1A—urinary bladder cancer	3.37e-06	7.22e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—PTEN—urinary bladder cancer	3.36e-06	7.21e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—RHOA—urinary bladder cancer	3.35e-06	7.17e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—ERBB2—urinary bladder cancer	3.34e-06	7.15e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—EP300—urinary bladder cancer	3.32e-06	7.12e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CCND1—urinary bladder cancer	3.32e-06	7.11e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—SRC—urinary bladder cancer	3.23e-06	6.92e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MMP9—urinary bladder cancer	3.22e-06	6.9e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—CDKN1A—urinary bladder cancer	3.21e-06	6.88e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—EP300—urinary bladder cancer	3.21e-06	6.87e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—MYC—urinary bladder cancer	3.21e-06	6.87e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—PTEN—urinary bladder cancer	3.2e-06	6.86e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PPARG—urinary bladder cancer	3.19e-06	6.83e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CXCL8—urinary bladder cancer	3.16e-06	6.78e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—PTEN—urinary bladder cancer	3.16e-06	6.77e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling by GPCR—HRAS—urinary bladder cancer	3.14e-06	6.73e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTGS2—urinary bladder cancer	3.14e-06	6.72e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—EGFR—urinary bladder cancer	3.14e-06	6.72e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—SRC—urinary bladder cancer	3.12e-06	6.68e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—ERBB2—urinary bladder cancer	3.1e-06	6.64e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—TP53—urinary bladder cancer	3.08e-06	6.59e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—CREBBP—urinary bladder cancer	3.06e-06	6.56e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EP300—urinary bladder cancer	3.06e-06	6.54e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—IL2—urinary bladder cancer	3.02e-06	6.48e-05	CbGpPWpGaD
Prazosin—ADRA2A—Metabolism—EP300—urinary bladder cancer	3.02e-06	6.46e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—SRC—urinary bladder cancer	2.97e-06	6.36e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—KRAS—urinary bladder cancer	2.96e-06	6.35e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CCND1—urinary bladder cancer	2.95e-06	6.32e-05	CbGpPWpGaD
Prazosin—HTR1D—Signaling Pathways—HRAS—urinary bladder cancer	2.94e-06	6.31e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CXCL8—urinary bladder cancer	2.94e-06	6.3e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling by GPCR—HRAS—urinary bladder cancer	2.92e-06	6.26e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—MYC—urinary bladder cancer	2.9e-06	6.2e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MMP9—urinary bladder cancer	2.86e-06	6.13e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—CDKN1A—urinary bladder cancer	2.85e-06	6.11e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—PTEN—urinary bladder cancer	2.85e-06	6.1e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—EGFR—urinary bladder cancer	2.83e-06	6.07e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—IL2—urinary bladder cancer	2.81e-06	6.02e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—MYC—urinary bladder cancer	2.8e-06	5.99e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CCND1—urinary bladder cancer	2.74e-06	5.87e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—PTEN—urinary bladder cancer	2.74e-06	5.86e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—EGFR—urinary bladder cancer	2.73e-06	5.86e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EP300—urinary bladder cancer	2.71e-06	5.81e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—KRAS—urinary bladder cancer	2.68e-06	5.73e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—MYC—urinary bladder cancer	2.66e-06	5.7e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MMP9—urinary bladder cancer	2.66e-06	5.7e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—CDKN1A—urinary bladder cancer	2.65e-06	5.68e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—PTEN—urinary bladder cancer	2.64e-06	5.66e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—SRC—urinary bladder cancer	2.64e-06	5.65e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—TP53—urinary bladder cancer	2.63e-06	5.64e-05	CbGpPWpGaD
Prazosin—CYP1A1—Metabolism—EP300—urinary bladder cancer	2.61e-06	5.59e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—EGFR—urinary bladder cancer	2.6e-06	5.58e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—KRAS—urinary bladder cancer	2.58e-06	5.53e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EP300—urinary bladder cancer	2.52e-06	5.4e-05	CbGpPWpGaD
Prazosin—ADRA1D—Signaling Pathways—HRAS—urinary bladder cancer	2.52e-06	5.4e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTGS2—urinary bladder cancer	2.51e-06	5.37e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—KRAS—urinary bladder cancer	2.46e-06	5.27e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—SRC—urinary bladder cancer	2.45e-06	5.25e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—TP53—urinary bladder cancer	2.38e-06	5.09e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—MYC—urinary bladder cancer	2.36e-06	5.07e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—EGFR—urinary bladder cancer	2.31e-06	4.95e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—TP53—urinary bladder cancer	2.3e-06	4.92e-05	CbGpPWpGaD
Prazosin—ADRA2B—Signaling Pathways—HRAS—urinary bladder cancer	2.27e-06	4.87e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—MYC—urinary bladder cancer	2.2e-06	4.71e-05	CbGpPWpGaD
Prazosin—HTR1A—Signaling Pathways—HRAS—urinary bladder cancer	2.2e-06	4.7e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—PTEN—urinary bladder cancer	2.19e-06	4.68e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—TP53—urinary bladder cancer	2.19e-06	4.68e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—KRAS—urinary bladder cancer	2.19e-06	4.68e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—EGFR—urinary bladder cancer	2.15e-06	4.6e-05	CbGpPWpGaD
Prazosin—ADRA1B—Signaling Pathways—HRAS—urinary bladder cancer	2.09e-06	4.48e-05	CbGpPWpGaD
Prazosin—ABCB1—Metabolism—EP300—urinary bladder cancer	2.09e-06	4.47e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—KRAS—urinary bladder cancer	2.03e-06	4.35e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—TP53—urinary bladder cancer	1.94e-06	4.16e-05	CbGpPWpGaD
Prazosin—ADRA1A—Signaling Pathways—HRAS—urinary bladder cancer	1.86e-06	3.98e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—TP53—urinary bladder cancer	1.8e-06	3.87e-05	CbGpPWpGaD
Prazosin—ADRA2A—Signaling Pathways—HRAS—urinary bladder cancer	1.73e-06	3.7e-05	CbGpPWpGaD
